IP Library Granted Patent US 7,964,183
Granted Patent B2
US 7,964,183 · App. 12/655,397 · Granted Jun 21, 2011

Composition and dosage form comprising a particle formulation and suspending vehicle

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,964,183
App. No.
12/655,397
Granted
Jun 21, 2011
Kind
B2
Abstract

A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

Claims (25)

1. A pharmaceutical composition comprising:

a particle formulation comprising a protein or peptide, sucrose, methionine, and citrate buffer, and

a suspending vehicle comprising a solvent selected from the group consisting of benzyl benzoate, lauryl lactate, and lauryl alcohol, wherein the particle formulation is dispersed in the suspending vehicle.

2. The pharmaceutical composition of claim 1 , wherein said protein or peptide is selected from the group consisting of erythropoietin, human growth hormone, granulocyte macrophage colony stimulating factor, human growth hormone releasing hormone, insulin, infliximab, and glucagon-like peptide-1.

3. The pharmaceutical composition of claim 2 , wherein the protein or peptide is glucagon-like peptide-1.

4. The pharmaceutical composition of claim 1 , wherein the particle formulation comprises the protein or peptide, sucrose, methionine, and citrate buffer in a weight ratio of 1:2:1:2.15.

5. The pharmaceutical composition of claim 4 , wherein the solvent is benzyl benzoate.

6. The pharmaceutical composition of claim 1 , wherein the solvent is benzyl benzoate.

7. The pharmaceutical composition of claim 1 , wherein the solvent is lauryl lactate.

8. The pharmaceutical composition of claim 1 , wherein the suspending vehicle further comprises a lipid.

9. The pharmaceutical composition of claim 8 , wherein the lipid is selected from the group consisting of dioleoyl phosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, partially hydrogenated phosphatidylcholines, fully hydrogenated phosphatidylcholines, palmitoyl-oleoyl phosphatidylcholine, stearyloleoylphosphatidylcholine, dioleoy phosphatidylglycerol, dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, and mixtures thereof.

10. The pharmaceutical composition of claim 1 , wherein the particle formulation comprises spray-dried particles.

11. The pharmaceutical composition of claim 10 , wherein the particle size is from about 1 μm to about 10 μm in diameter.

12. An osmotic drug delivery device comprising

a pharmaceutical composition comprising, (i) a particle formulation comprising a protein or peptide, sucrose, methionine, and citrate buffer, and (ii) a suspending vehicle comprising a solvent selected from the group consisting of benzyl benzoate, lauryl lactate, and lauryl alcohol, wherein the particle formulation is dispersed in the suspending vehicle.

13. The osmotic drug delivery device of claim 12 , wherein said protein or peptide is selected from the group consisting of erythropoietin, human growth hormone, granulocyte macrophage colony stimulating factor, human growth hormone releasing hormone, insulin, infliximab, and glucagon-like peptide-1.

14. The osmotic drug delivery device of claim 13 , wherein the protein or peptide is glucagon-like peptide-1.

15. The osmotic drug delivery device of claim 12 , wherein the particle formulation comprises the protein or peptide, sucrose, methionine, and citrate buffer in a weight ratio of 1:2:1:2.15.

16. The osmotic drug delivery device of claim 15 , wherein the solvent is benzyl benzoate.

17. The osmotic drug delivery device of claim 12 , wherein the solvent is benzyl benzoate.

18. The osmotic drug delivery device of claim 12 , wherein the solvent is lauryl lactate.

19. The osmotic drug delivery device of claim 12 , wherein the suspending vehicle further comprises a lipid.

20. The osmotic drug delivery device of claim 19 , wherein the lipid is selected from the group consisting of dioleoyl phosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, partially hydrogenated phosphatidylcholines, fully hydrogenated phosphatidylcholines, palmitoyl-oleoyl phosphatidylcholine, stearyloleoylphosphatidylcholine, dioleoy phosphatidylglycerol, dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, and mixtures thereof.

21. The osmotic drug delivery device of claim 12 , wherein the particle formulation comprises spray-dried particles.

22. The osmotic drug delivery device of claim 21 , wherein the particle size is from about 1 μm to about 10 μm in diameter.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
Reel/Frame 052433/0001 →
RELEASE OF SECURITY INTEREST Recorded Jan 29, 2020
From: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 051739/0453 →
SECURITY INTEREST Recorded Oct 23, 2019
From: INTARCIA THERAPEUTICS, INC.
To: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT
Reel/Frame 050801/0267 →
SECURITY INTEREST Recorded Oct 9, 2019
From: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050673/0020 →
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2015
From: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 036942/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: ALZA CORPORATION
To: INTARCIA THERAPEUTICS INC.
Reel/Frame 035233/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: ELIAZ, ROM EZER; ZHANG, YUANPENG; ROHLOFF, CATHERINE MANYA; WEEKS, ERIC WILLIAM; JUNNARKAR, GUNJAN
To: ALZA CORPORATION
Reel/Frame 035233/0597 →
SECURITY AGREEMENT Recorded Nov 14, 2012
From: INTARCIA THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029299/0678 →
RELEASE OF SECURITY INTEREST Recorded Sep 23, 2011
From: OXFORD FINANCE CORPORATION; SILICON VALLEY BANK
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 026962/0062 →
SECURITY AGREEMENT Recorded Sep 8, 2010
From: INTARCIA THERAPEUTICS, INC.
To: OXFORD FINANCE CORPORATION; SILICON VALLEY BANK
Reel/Frame 024953/0525 →